Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo

Yanyun Du; Jiawang Gao; Mengjiao He; Ming Yi; Jiaqi Wu; Lingyun Feng; Bo Zeng; Yangyang Li; Ruirui He; Yuan Wang; Cheng-Feng Qin; Zongqiang Cui; Chenhui Wang

doi:10.1111/imm.13889

Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo

Immunology. 2025 Jan 9. doi: 10.1111/imm.13889. Online ahead of print.

Authors

Yanyun Du^{1

2

3

4}, Jiawang Gao^{5

6}, Mengjiao He^{7

8}, Ming Yi^{1

2

3

4}, Jiaqi Wu^{1

2

3

4}, Lingyun Feng^{1

2

3

4}, Bo Zeng^{1

2

3

4}, Yangyang Li^{1

2

3

4}, Ruirui He^{1

2

3

4}, Yuan Wang⁴, Cheng-Feng Qin^{7

8}, Zongqiang Cui^{5

6}, Chenhui Wang^{1

2

3

4}

Affiliations

¹ The Key Laboratory for Human Disease Gene Study of Sichuan Province, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
² Sichuan Medical Laboratory Clinical Medical Research Center, Sichuan Provincial People's Hospital, Chengdu, China.
³ Research Unit for Blindness Prevention of the Chinese Academy of Medical Sciences, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
⁴ School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
⁵ State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, P.R. China.
⁶ University of Chinese Academy of Sciences, Beijing, P.R. China.
⁷ State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS), Beijing, China.
⁸ Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 39783143
DOI: 10.1111/imm.13889

Abstract

Many virus species, including Ebola virus, Marburg virus, SARS-CoV-2, dengue virus (DENV) and Zika virus (ZIKV), exploit CD209 and CD209L as alternative or attachment receptors for viral cis- or trans-infection. Thus, CD209 and CD209L may be critical targets for the development of therapeutic monoclonal blocking antibody drugs to disrupt the infection process caused by multiple viruses. Here, we produced a human chimeric monoclonal blocking antibody that simultaneously blocks CD209 and CD209L, namely 7-H7-B1. We show that 7-H7-B1 effectively blocks multiple pseudotyped or live viral infections in vitro, including SARS-CoV, SARS-CoV-2, Ebola virus, Marburg virus, ZIKV and DENV infections. However, the 7-H7-B1 mAb does not provide favourable protection against Zaire Ebola virus or ZIKV infection in hCD209 knock-in mice in vivo. Thus, our findings indicate that although CD209 and CD209L are critical for multiple viral infections in vitro, they may play only a partial role in viral infections in vivo.

Keywords: CD209 and CD209L; monoclonal antibody; viral infection.

Associated data

RefSeq/AF086833
RefSeq/KU955593
RefSeq/AY037116.1

Abstract

Associated data

Grants and funding